Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 7, 2009, Pages 1075-1080

  Saidi, S ^a   Mahjoub, T ^a   Almawi, Wassim Y ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Antiphospholipid antibodies; Ischemic stroke; Lupus anticoagulant; Thrombosis

Indexed keywords

ANNEXIN 5 ANTIBODY; ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; BRAIN VENTRICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBOLISM; FEMALE; HEART DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; RISK FACTOR;

AGED; ANTIBODIES, ANTIPHOSPHOLIPID; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 67649479379     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03446.x     Document Type: Article

References (36)

1. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CD. Ethnic differences in incidence of stroke: Prospective study with stroke register. BMJ 1999; 318: 967-71.
2. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, the TOAST Investigators. Classification of subtype of acute ischemic stroke. Stroke 1993; 24: 35-41.
3. Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: A meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med 2007; 4: E131.
4. Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: A meta-analysis. J Hum Genet 2007; 52: 205-19.
5. Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaff M, Annichino Bizzacchi JM, Arruda VR. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83: 229-33.
6. Gao X, Yang H, Zhiping T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett 2006; 398: 172-7.
7. Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke 2004; 35: 736-41.
8. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies -co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91: 967-76.
9. Lien LM, Chen WH, Chiu HC, Pan WH, Chen JR, Bai CH. High titer of anticardiolipin antibody is associated with first-ever ischemic stroke in Taiwan. Cerebrovasc Dis 2006; 22: 225-30.
10. Tuhrim S, Rand JH, Wu X, Horowitz DR, Weinberger J, Goldman ME, Godbold JH. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999; 53: 1523-7.
11. Gonzales-Portillo F, McIntyre JA, Wagenknecht DR, Williams LS, Bruno A, Biller J. Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 2001; 10: 222-6.
12. Cheng H-W. Pathogenicity of antiphospholipid antibodies. In: Immunophysiology of Antiphospholipid Antibodies. Austin, TX: RG Landes Co, 1994: 67-89.
13. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000; 15: 163-72.
14. Luong TH, Rand JH, Wu XX, Godbold JH, Gascon-Lema M, Tuhrim S. Seasonal distribution of antiphospholipid antibodies. Stroke 2001; 32: 1707-11.
15. Rand JH. Antiphospholipid antibody syndrome: New insights on thrombogenic mechanism. Am J Med Sci 1998; 316: 142-51.
16. Schultz DR. Antiphospholipid antibodies: Basic immunology and assays. Semin Arthritis Rheum 1997; 26: 724-39.
17. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995; 74: 1185-90.
18. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101: 1827-32.
19. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-93.
20. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396-400.
21. Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, Godbold JH. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999; 30: 1561-5.
22. Heinzlef O, Abuaf N, Cohen A, Amarenco P; French Study of Aortic Plaques in Stroke Group. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: A prospective study. J Neurol 2001; 248: 373-9.
23. Metz LM, Edworthy S, Mydlarski R, Fritzler MJ. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci 1998; 25: 64-9.
24. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998; 29: 2245-53.
25. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study. Neuroepidemiology 2002; 21: 93-9.
26. Jerrard-Dunne P, Evans A, McGovern R, Hajat C, Kalra L, Rudd AG, Wolfe CD, Markus HS. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: The South London Ethnicity and Stroke Study. Stroke 2003; 34: 1821-6.
27. Markus HS, Khan U, Birns J, Evans A, Kalra L, Rudd AG, Wolfe CD, Jerrard-Dunne P. Differences in stroke subtypes between black and white patients with stroke: The South London Ethnicity and Stroke Study. Circulation 2007; 116: 2157-64.
28. Hajat C, Tilling K, Stewart JA, Lemic-Stojcevic N, Wolfe CD. Ethnic differences in risk factors for ischemic stroke: A European case-control study. Stroke 2004; 35: 1562-7.
29. Jones JV, Eastwood BJ, Jones E, James H, Mansour M. Antiphospholipid antibodies in a healthy population: Methods for estimating the distribution. J Rheumatol 1995; 22: 55-61.
30. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke 2000; 31: 1289-93.
31. Triplett DA. Use of dilute Russell Viper Venom Time (dRVVT); its importance and pitfalls. J Autoimmun 2000; 15: 173-8.
32. Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998; 29: 1759-64.
33. Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology 2005; 44: 1161-5.
34. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 2005; 12: 429-34.
35. Camerlingo M, Casto L, Censori B, Drago G, Frigeni A, Ferraro B, Servalli MC, Radice E, Mamoli A. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995; 92: 69-71.
36. Zieliñska J, Ryglewicz D, Wierzchowska E, Lechowicz W, Hier DB, Czlonkowska A. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res 1999; 21: 653-7.